Long-Acting Beta Agonist

BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients started a new inhaled treatment in 2022, according to a presentation at the CHEST Annual Meeting.

When diagnosed with COPD, 86.2% of patients did not receive treatment, and after 4 years, 63.8% still had not been treated, according to results published in BMC Pulmonary Medicine.

BOSTON — Among adults with COPD starting a new inhaled maintenance treatment, common characteristics included older age and having multiple comorbidities, according to a poster presented at the CHEST Annual Meeting.

A medium inhaled corticosteroid dose plus a long-acting beta agonist was found to be the most beneficial step-up treatment option for children with uncontrolled asthma, according to a meta-analysis published in European Respiratory Journal.

Glycopyrronium/indacaterol reduced the likelihood for severe acute exacerbations and cardiovascular events compared with tiotropium/olodaterol among patients with COPD, according to study results published in CHEST.

WASHINGTON — The use of single-inhaler and multiple-inhaler therapies for asthma control as needed offers a variety of pros and cons, according to a presentation at the American Thoracic Society International Conference.

Across cohorts of patients with COPD, withdrawing inhaled corticosteroids from triple therapy resulted in similar FEV1 declines as remaining on triple therapy, according to a study published in Annals of the American Thoracic Society.

LOUISVILLE, Ky. — Patients with asthma faced high risks for exacerbations despite their maintenance medication or disease severity, reported researchers at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients with asthma who began triple therapy with a single inhaler had better adherence than patients on triple therapy with multiple inhalers, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Maintenance and reliever therapy using inhaled corticosteroids and formoterol was associated with lower risk for asthma exacerbations, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.